News

The company is focused on the development of new medications to help patients with cognitive disorders, including ADHD and Fragile X Syndrome. The 300-patient, randomized, placebo-controlled trial was

The contract is aimed at advancing development of the company’s thermostabilization technology, ThermoVax, combined with its ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the

The programs will focus on ‘last-mile’ interventions to reach underserved populations living in Ethiopia, Malawi, Rwanda, Uganda and Zambia. Grant recipients include UNICEF, Save the Children and International

Bardet-Biedl syndrome (BBS) is an inherited disease that causes blindness, learning difficulties, extra fingers and toes and obesity and can lead to serious kidney problems. It affects around

The acquisition further accelerates Horizon’s transformation into a profitable specialty biopharmaceutical company and provides a strong operating and financial platform for future growth. The Company has over 500

In the Phase III PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) trial, the addition of LBH589 also led to clinically meaningful increases in complete and near complete response rates

In the study, lung fibrosis, as measured by quantitative high resolution computed tomography (HRCT), was reduced in a substantial portion of patients who received FG-3019. FG-3019 is a

Biotec is a provider of clinical trials and temperature controlled pharmaceutical services. The company said that the acquisition will help in expanding its presence in the UK/EU region

Zydelig is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, which plays a major role in the activation, proliferation and viability of B cells, a critical component of